Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
Key Points
According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Stock shares on June 18, 2026, generating a transaction value of $490,000.
The sale represented 17.8% of Williams's direct Common Stock holdings, reducing her Common Stock position to 378,195 shares (direct) post-transaction.
This transaction involved the exercise of 31,000 stock options, immediately followed by the sale of shares; no indirect holdings or gifting activity was reported.
- 10 stocks we like better than Ardelyx ›
On June 22, 2026, Ardelyx (NASDAQ:ARDX) Chief Patient Officer Laura Williams reported the sale of 81,898 shares of Common Stock for a transaction value of approximately $490,000, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 81,898 |
| Transaction value | $490,000 |
| Post-transaction common shares (direct) | 378,195 |
| Post-transaction value (direct ownership) | $2.29 million |
Transaction value based on SEC Form 4 weighted average purchase price ($5.99); post-transaction value based on June 18, 2026 market close ($6.05).
Key questions
- How did this transaction impact Laura Williams's direct ownership stake?
Williams's direct Common Stock holdings decreased by 17.8%, from 460,093 to 378,195 shares, reflecting a sizable but not total reduction of her position. - What is the derivative context for this transaction?
The sale followed the exercise of 31,000 stock options, with the resulting shares immediately sold as part of the disclosed transaction; Williams continues to hold 31,000 stock options eligible for future conversion to Common Stock, according to the Form 4 filing. - How does the sale relate to Ardelyx's current market environment?
The transaction was completed following a one-year total return of roughly 70% for Ardelyx shares as of June 18, implying the sale captured value following substantial share price appreciation.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close June 18, 2026) | $5.99 |
| Market capitalization | $1.57 billion |
| Revenue (TTM) | $427.68 million |
| Net income (TTM) | -$58.06 million |
* 1-year performance is calculated using June 18, 2026 as the reference date.
Company snapshot
- Ardelyx develops and commercializes therapeutics targeting gastrointestinal and cardiorenal diseases, with tenapanor as its lead product for IBS-C and hyperphosphatemia; additional pipeline assets include RDX013 (for hyperkalemia) and RDX020 (for metabolic acidosis).
- The company generates revenue primarily through product sales and strategic out-licensing agreements for tenapanor in international markets, leveraging partnerships with Kyowa Kirin, Fosun Pharmaceutical, and Knight Therapeutics.
- Key customers include healthcare providers, nephrologists, and gastroenterologists treating patients with chronic kidney disease, irritable bowel syndrome with constipation, and related metabolic disorders.
Ardelyx operates at scale within the biotechnology sector, focusing on innovative therapies for unmet needs in gastrointestinal and cardiorenal health. The company's strategy combines internal product development with global partnerships to maximize market reach and accelerate commercialization. Its differentiated pipeline and established collaborations position Ardelyx as a specialized leader addressing complex conditions in nephrology and gastroenterology.
What this transaction means for investors
By the time of this sale, Ardelyx stock had rallied roughly 70% over the prior year, making some profit-taking understandable. But perhaps more importantly, the filing states that the transaction was made pursuant to a 10b5-1 trading plan. While Williams sold nearly 82,000 shares, she still owns 378,195 shares outright and retains 31,000 stock options, leaving her with meaningful exposure to future upside.
Operationally, Ardelyx continues to execute. First-quarter product revenue climbed 38% year over year to $93.4 million, driven by 58% growth in IBSRELA revenue to $70.1 million. Management reiterated 2026 guidance for IBSRELA revenue of $410 million to $430 million and XPHOZAH revenue of $110 million to $120 million. The company also finished the quarter with $238.1 million in cash, cash equivalents, and investments.
CEO Mike Raab said Ardelyx's "strong commercial execution" and strengthening cash position are allowing the company to invest in new clinical trials, advance its next-generation pipeline, and pursue additional growth opportunities. He added that IBSRELA remains on a path toward becoming a “blockbuster” product with plans for at least $1 billion in revenue in 2029.
For long-term investors, the bigger story is whether Ardelyx can sustain the commercial momentum behind IBSRELA and expand its cardiorenal and gastrointestinal franchise. This sale reduced Williams' stake, but her remaining ownership suggests continued alignment with shareholders. Strong revenue growth, expanding indications, and a healthy balance sheet remain the factors most likely to drive returns from here.
Should you buy stock in Ardelyx right now?
Before you buy stock in Ardelyx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ardelyx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $393,037!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,280,627!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Ardelyx. The Motley Fool has a disclosure policy.
Recommended Articles
